Burimamide: Difference between revisions
Content deleted Content added
Updating {{chembox}} (changes to watched fields) per Chem/infobox_drug validation (report errors or bugs) |
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.5beta) |
||
| Line 51: | Line 51: | ||
'''Burimamide''' is an [[Receptor antagonist|antagonist]] at the [[Histamine H2 receptor|H<sub>2</sub>]] and [[Histamine H3 receptor|H<sub>3</sub>]] [[histamine]] [[Receptor (biochemistry)|receptors]]. It is largely inactive as an H<sub>2</sub> antagonist at physiological pH,<ref name="Clayden">{{Clayden|page=205}}</ref> but its H<sub>3</sub> affinity is 100x higher. It is a [[thiourea]] derivative. |
'''Burimamide''' is an [[Receptor antagonist|antagonist]] at the [[Histamine H2 receptor|H<sub>2</sub>]] and [[Histamine H3 receptor|H<sub>3</sub>]] [[histamine]] [[Receptor (biochemistry)|receptors]]. It is largely inactive as an H<sub>2</sub> antagonist at physiological pH,<ref name="Clayden">{{Clayden|page=205}}</ref> but its H<sub>3</sub> affinity is 100x higher. It is a [[thiourea]] derivative. |
||
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now [[GlaxoSmithKline]]) in their intent to develop a histamine antagonist for the treatment of [[peptic ulcers]].<ref name="ACS Landmarks">{{cite web |url = http://portal.acs.org/portal/PublicWebSite/education/whatischemistry/landmarks/cimetidinetagamet/ |title = Tagamet<sup>®</sup>: Discovery of Histamine H<sub>2</sub>-receptor Antagonists |publisher = American Chemical Society |work = National Historic Chemical Landmarks |accessdate= June 25, 2012}}</ref> The discovery of burimamide ultimately led to the development of [[cimetidine]] (Tagamet).<ref name="ACS Landmarks"/> |
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now [[GlaxoSmithKline]]) in their intent to develop a histamine antagonist for the treatment of [[peptic ulcers]].<ref name="ACS Landmarks">{{cite web |url = http://portal.acs.org/portal/PublicWebSite/education/whatischemistry/landmarks/cimetidinetagamet/ |title = Tagamet<sup>®</sup>: Discovery of Histamine H<sub>2</sub>-receptor Antagonists |publisher = American Chemical Society |work = National Historic Chemical Landmarks |accessdate = June 25, 2012 |deadurl = yes |archiveurl = https://archive.is/20121209003707/http://portal.acs.org/portal/PublicWebSite/education/whatischemistry/landmarks/cimetidinetagamet/ |archivedate = December 9, 2012 |df = }}</ref> The discovery of burimamide ultimately led to the development of [[cimetidine]] (Tagamet).<ref name="ACS Landmarks"/> |
||
==See also== |
==See also== |
||
Revision as of 16:41, 27 July 2017
| |
| |
| Names | |
|---|---|
| IUPAC name
1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C9H16N4S | |
| Molar mass | 212.32 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Burimamide is an antagonist at the H2 and H3 histamine receptors. It is largely inactive as an H2 antagonist at physiological pH,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).[2]
See also
References
- ^ Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0.
- ^ a b "Tagamet®: Discovery of Histamine H2-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Archived from the original on December 9, 2012. Retrieved June 25, 2012.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |